Relmada Therapeutics, Inc.

RLMD ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › SEC Filings

SEC Filings

Form Filed Description
4 Sep 11, 2026 OWNERSHIP DOCUMENT
4 Sep 11, 2026
8-K Sep 8, 2026 CURRENT REPORT
SCHEDULE 13G/A Aug 14, 2026
8-K Aug 6, 2026 CURRENT REPORT
10-Q Aug 6, 2026 QUARTERLY REPORT
SCHEDULE 13G Jul 29, 2026
8-K Jul 28, 2026 CURRENT REPORT
SCHEDULE 13G Jun 22, 2026
S-8 Jun 18, 2026 REGISTRATION STATEMENT
SCHEDULE 13G Jun 9, 2026
8-K May 28, 2026 CURRENT REPORT
S-3ASR May 13, 2026 REGISTRATION STATEMENT
SCHEDULE 13G/A May 13, 2026
8-K May 12, 2026 CURRENT REPORT
10-Q May 12, 2026 QUARTERLY REPORT
SCHEDULE 13G May 4, 2026
DEFA14A Apr 17, 2026 DEFINITIVE ADDITIONAL MATERIALS
DEF 14A Apr 17, 2026 PROXY STATEMENT
EFFECT Apr 9, 2026
424B3 Apr 9, 2026 PROSPECTUS
CORRESP Apr 7, 2026
UPLOAD Apr 7, 2026
PRE 14A Apr 6, 2026 PROXY STATEMENT
S-3 Apr 3, 2026 REGISTRATION STATEMENT
← Newer Page 1 of 25 · 606 filings Older →